OraSure (OSUR) Target Raised at Canaccord Genuity After Confirming Ebola Test

October 16, 2014 8:40 AM EDT
Get Alerts OSUR Hot Sheet
Price: $5.65 +0.71%

Rating Summary:
    9 Buy, 8 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 7 | New: 42
Join SI Premium – FREE

Canaccord Genuity analyst Mark Massaro boosted his price target on Buy-rated OraSure Technologies (NASDAQ: OSUR) to $12.00 (from $11.00) on a report the company has visited with FDA this week to discuss feasibility to develop an Ebola test.

Massaro "We spoke with OSUR management, who confirmed they are seeking to develop a test. We believe OSUR has multiple shots on goal. We raise our Street-high price target to $12, based on a modest increase in multiple expansion (to 5.5x from 5.0x) on our unchanged ‘15 rev. estimate."

The analyst added, "OSUR has confirmed it has engaged in talks with private sector entities and federal agencies (we suspect FDA and CDC to name two) and have been working to develop an Ebola test for ~3 weeks. We believe OSUR’s rapid HIV and HCV oral-fluid tests are unique assets, and we’re not surprised that OSUR’s platform technology has the potential ability to help curb the Ebola outbreak."

For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.

Shares of OraSure Technologies closed at $8.34 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA, Hot Comments, Momentum Movers, Trader Talk

Related Entities

Canaccord Genuity